Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Avelumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    94 result(s) found for: Avelumab. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2021-002457-29 Sponsor Protocol Number: B9991046 Start Date*: 2021-12-23
    Sponsor Name:Pfizer Inc.
    Full Title: AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES
    Medical condition: This Master Protocol for Avelumab Continuation Sub-Studies has been designed to accommodate continued access to study intervention, safety follow-up, and when applicable, overall survival follow up...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003711-21 Sponsor Protocol Number: MS100070_0176 Start Date*: 2019-08-29
    Sponsor Name:Merck KGaA
    Full Title: An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) HU (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003091-77 Sponsor Protocol Number: B9991009 Start Date*: 2016-03-16
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin Alone to In Patien...
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) AT (Completed) ES (Completed) GR (Completed) IE (Completed) NL (Completed) FR (Completed) PL (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003262-86 Sponsor Protocol Number: B9991001 Start Date*: 2016-06-06
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN...
    Medical condition: Locally advanced or metastatic urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) SE (Completed) BE (Completed) CZ (Completed) PT (Completed) DK (Completed) ES (Ongoing) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001537-24 Sponsor Protocol Number: EMR100070-005 Start Date*: 2015-12-14
    Sponsor Name:Merck KGaA
    Full Title: A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer
    Medical condition: First Line Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) PT (Completed) LT (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) HU (Completed) PL (Completed) NL (Completed) FR (Completed) DK (Completed) BG (Completed) HR (Completed) CY (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002227-42 Sponsor Protocol Number: UCL/17/0192 Start Date*: 2019-02-14
    Sponsor Name:University College London
    Full Title: Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study
    Medical condition: Advanced classical Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001456-21 Sponsor Protocol Number: B9991016 Start Date*: 2017-05-09
    Sponsor Name:Pfizer Inc.
    Full Title: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN...
    Medical condition: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Prematurely Ended) DE (Prematurely Ended) PL (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IE (Completed) PT (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005060-15 Sponsor Protocol Number: EMR100070-004 Start Date*: 2015-06-23
    Sponsor Name:Merck KGaA
    Full Title: A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Prematurely Ended) GB (Completed) BE (Completed) HU (Completed) DK (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) CZ (Completed) PL (Completed) HR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2015-003239-36 Sponsor Protocol Number: B9991010 Start Date*: 2016-08-22
    Sponsor Name:Pfizer Inc.
    Full Title: A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Unt...
    Medical condition: Epithelial ovarian cancer (EOC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) EE (Completed) IE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) DE (Completed) PL (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002429-20 Sponsor Protocol Number: B9991003 Start Date*: 2016-08-05
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) ) MONOTHERAPY IN THE FIRST-LINE TRE...
    Medical condition: Advanced renal cell carcinoma (aRCC).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10023405 Kidney cancer stage IV LLT
    21.0 100000004864 10023404 Kidney cancer stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Ongoing) SE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) AT (Completed) DK (Completed) ES (Temporarily Halted) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001708-12 Sponsor Protocol Number: 4518000 Start Date*: 2018-12-19
    Sponsor Name:Alcedis GmbH
    Full Title: A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cu...
    Medical condition: Unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001741-27 Sponsor Protocol Number: B9991023 Start Date*: 2018-03-28
    Sponsor Name:Pfizer Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LIN...
    Medical condition: Advanced malignances in the first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) HU (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004456-30 Sponsor Protocol Number: B9991030 Start Date*: 2018-09-13
    Sponsor Name:Pfizer Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH...
    Medical condition: PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) EE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003669-36 Sponsor Protocol Number: MS100070_0119 Start Date*: 2022-09-13
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with L...
    Medical condition: Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) ES (Trial now transitioned) FR (Trial now transitioned) DK (Completed) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004403-31 Sponsor Protocol Number: MITOEND-3 Start Date*: 2022-03-24
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: MITO END-3: A randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (stage III-IV) or recurrent endometrial cancer
    Medical condition: advanced (stage III-IV) or recurrent endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007342 Carcinoma endometrial LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001427-38 Sponsor Protocol Number: P/2017/337 Start Date*: 2018-07-04
    Sponsor Name:CHU Besançon
    Full Title: Activité et tolérance d’une immunothérapie par avelumab en maintenance après une première ligne de polychimiothérapie contenant un sel de platine chez les patients atteints de carcinome épidermoïde...
    Medical condition: carcinome épidermoïde de verge
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002985-28 Sponsor Protocol Number: MS100070-0306 Start Date*: 2018-03-02
    Sponsor Name:Merck KGaA
    Full Title: Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics, safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractor...
    Medical condition: Solid tumors (including central nervous system tumors) and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10065143 Malignant solid tumour LLT
    20.0 100000004864 10025632 Malignant lymphoma LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000124-34 Sponsor Protocol Number: B9991033 Start Date*: 2019-02-19
    Sponsor Name:Pfizer Inc, 253 East 42nd Street, New York, NY 10017
    Full Title: A Phase 1b/2, study to evaluate safety and clinical activity of avelumab in combination with binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-Mutant Solid...
    Medical condition: locally advanced or metastatic KRAS-or NRAS-mutant NSCLC, mPDAC (regardless of KRAS status), and other KRAS-or NRAS-mutant solid tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065147 Malignant solid tumor LLT
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001509-33 Sponsor Protocol Number: B9991025 Start Date*: 2018-05-31
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH ...
    Medical condition: Locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hormone receptor-positive (HR+) / human epide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065147 Malignant solid tumor LLT
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DK (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-004098-23 Sponsor Protocol Number: Tide-A Start Date*: 2020-06-18
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 03:44:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA